Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (756) 756
Patent (46) 46
Book Chapter (5) 5
Publication (3) 3
Government Document (2) 2
Web Resource (2) 2
Book / eBook (1) 1
Book Review (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (379) 379
life sciences & biomedicine (344) 344
humans (338) 338
imatinib mesylate (159) 159
biological and medical sciences (156) 156
hematology (149) 149
benzamides (145) 145
animals (143) 143
oncology (123) 123
medical sciences (119) 119
mice (114) 114
abridged index medicus (113) 113
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (109) 109
pyrimidines - therapeutic use (90) 90
phosphorylation (86) 86
hemic and lymphatic diseases (84) 84
piperazines - therapeutic use (81) 81
pyrimidines - pharmacology (81) 81
hematologic and hematopoietic diseases (78) 78
antineoplastic agents - therapeutic use (74) 74
female (73) 73
piperazines - pharmacology (73) 73
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (72) 72
mutation (68) 68
antineoplastic agents (67) 67
male (67) 67
leukemia (66) 66
fusion proteins, bcr-abl - genetics (62) 62
protein-tyrosine kinases - antagonists & inhibitors (62) 62
signal transduction (62) 62
cell line, tumor (60) 60
pharmacology. drug treatments (60) 60
fusion proteins, bcr-abl - metabolism (57) 57
leukemia, myelogenous, chronic, bcr-abl positive - genetics (57) 57
middle aged (56) 56
biochemistry & molecular biology (55) 55
cell biology (55) 55
adult (54) 54
antineoplastic agents - pharmacology (51) 51
cancer (51) 51
aged (49) 49
cell line (48) 48
chemotherapy (45) 45
tumor cells, cultured (44) 44
protein kinase inhibitors - pharmacology (43) 43
chemistry (42) 42
chronic myeloid leukemia (42) 42
leukemia, myelogenous, chronic, bcr-abl positive - pathology (41) 41
metallurgy (41) 41
fundamental and applied biological sciences. psychology (39) 39
protein-tyrosine kinases - metabolism (39) 39
organic chemistry (38) 38
research (37) 37
tyrosine - metabolism (36) 36
drug resistance, neoplasm (35) 35
science & technology - other topics (35) 35
multidisciplinary sciences (34) 34
tumors (34) 34
signal transduction - drug effects (33) 33
adaptor proteins, signal transducing (32) 32
proteins (32) 32
treatment outcome (32) 32
genetic aspects (31) 31
bcr-abl (30) 30
fusion proteins, bcr-abl - antagonists & inhibitors (30) 30
molecular and cellular biology (30) 30
tyrosine (30) 30
protein kinase inhibitors - therapeutic use (29) 29
proto-oncogene proteins - metabolism (29) 29
apoptosis - drug effects (28) 28
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (28) 28
molecular sequence data (28) 28
neoplasms (28) 28
dose-response relationship, drug (27) 27
human necessities (27) 27
hygiene (27) 27
medical or veterinary science (27) 27
piperazines - administration & dosage (27) 27
preparations for medical, dental, or toilet purposes (27) 27
pyrimidines - administration & dosage (27) 27
imatinib (26) 26
medicine, research & experimental (26) 26
phosphorylation - drug effects (26) 26
research & experimental medicine (26) 26
specific therapeutic activity of chemical compounds ormedicinal preparations (26) 26
enzyme inhibitors - pharmacology (25) 25
health aspects (25) 25
myeloid leukemia (25) 25
protein-tyrosine kinases - genetics (25) 25
transfection (25) 25
amino acid sequence (24) 24
heterocyclic compounds (24) 24
piperazines - adverse effects (24) 24
pyrimidines - adverse effects (24) 24
drug therapy (23) 23
cell physiology (22) 22
kinases (22) 22
nuclear proteins - metabolism (22) 22
antineoplastic agents - administration & dosage (21) 21
antineoplastic agents - adverse effects (21) 21
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (2) 2
Baycrest Hospital - Course Reserves (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Gerstein Science - Course Reserves (1) 1
Gerstein Science - Stacks (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Providence Healthcare - Reference (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
St Josephs Health Centre - Reference (1) 1
St. Michael's Hospital - Circulation Desk (1) 1
St. Michael's Hospital - Stacks (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
Women's College Hospital - Pharmacy (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (808) 808
French (9) 9
German (5) 5
Portuguese (3) 3
Norwegian (2) 2
Spanish (2) 2
Chinese (1) 1
Danish (1) 1
Hungarian (1) 1
Japanese (1) 1
Polish (1) 1
Slovak (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Perspectives on the development of imatinib and the future of cancer research
by Druker, Brian J
Nature medicine, ISSN 1078-8956, 10/2009, Volume 15, Issue 10, pp. 1149 - 1152
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Piperazines - history | History, 21st Century | Protein Kinase Inhibitors - history | United States | History, 20th Century | Humans | Awards and Prizes | Clinical Trials as Topic | Piperazines - therapeutic use | Imatinib Mesylate | Neoplasms - drug therapy | Research - trends | Pyrimidines - history | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Benzamides | Forecasts and trends | Research | Drug therapy | Oncology, Experimental | Leukemia in children | Cancer | Oncology | Chemotherapy | Biomedical research | Brian J Druker | Leukemia | Index Medicus | Druker
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Goodman & Gilman's The pharmacological basis of therapeutics
by Goodman, Louis S. 1906-2000 (Louis Sanford) and Brunton, Laurence L and Chabner, Bruce and Knollmann, Björn C
2011, 12th ed., McGraw-Hill's AccessMedicine, ISBN 0071624422, 2047
Pharmacology | Pharmacological Phenomena | Therapeutics | Drug Therapy | Chemotherapy
eBook
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
by Zabriskie, Matthew S and Eide, Christopher A and Tantravahi, Srinivas K and Vellore, Nadeem A and Estrada, Johanna and Nicolini, Franck E and Khoury, Hanna J and Larson, Richard A and Konopleva, Marina and Cortes, Jorge E and Kantarjian, Hagop and Jabbour, Elias J and Kornblau, Steven M and Lipton, Jeffrey H and Rea, Delphine and Stenke, Leif and Barbany, Gisela and Lange, Thoralf and Hernández-Boluda, Juan-Carlos and Ossenkoppele, Gert J and Press, Richard D and Chuah, Charles and Goldberg, Stuart L and Wetzler, Meir and Mahon, Francois-Xavier and Etienne, Gabriel and Baccarani, Michele and Soverini, Simona and Rosti, Gianantonio and Rousselot, Philippe and Friedman, Ran and Deininger, Marie and Reynolds, Kimberly R and Heaton, William L and Eiring, Anna M and Pomicter, Anthony D and Khorashad, Jamshid S and Kelley, Todd W and Baron, Riccardo and Druker, Brian J and Deininger, Michael W and O’Hare, Thomas
Cancer cell, ISSN 1535-6108, 09/2014, Volume 26, Issue 3, pp. 428 - 442
Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Fusion Proteins, bcr-abl - chemistry | Catalytic Domain | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Imidazoles - pharmacology | Mutation, Missense | Pyridazines - pharmacology | Antineoplastic Agents - chemistry | Molecular Dynamics Simulation | Pyridazines - chemistry | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Treatment Failure | Protein Binding | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Imidazoles - therapeutic use | Philadelphia Chromosome | Pyridazines - therapeutic use | Leukemia | Genetic aspects | Cancer | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Imatinib: A Viewpoint by Brian J. Druker
by Druker B.J
Drugs (New York, N.Y.), ISSN 0012-6667, 2001, Volume 61, Issue 12, pp. 1775 - 1776
Chronic myeloid leukaemia, treatment | Tyrosine kinase inhibitors, general | New drug profiles | Antineoplastics, general | Imatinib mesylate, general | Research and development | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Translation of the Philadelphia chromosome into therapy for CML
by Druker, Brian J
Blood, ISSN 0006-4971, 12/2008, Volume 112, Issue 13, pp. 4808 - 4817
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Piperazines - history | History, 21st Century | History, 20th Century | Humans | Biomedical Research - history | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Pyrimidines - pharmacology | Drug Delivery Systems - history | Imatinib Mesylate | Piperazines - pharmacology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - history | Pyrimidines - history | Benzamides | Philadelphia Chromosome - drug effects | Drug Delivery Systems - methods | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
by Hochhaus, Andreas and Larson, Richard A and Guilhot, François and Radich, Jerald P and Branford, Susan and Hughes, Timothy P and Baccarani, Michele and Deininger, Michael W and Cervantes, Francisco and Fujihara, Satoko and Ortmann, Christine-Elke and Menssen, Hans D and Kantarjian, Hagop and O’Brien, Stephen G and Druker, Brian J and IRIS Investigators
The New England journal of medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Interferon-alpha - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Cross-Over Studies | Young Adult | Imatinib Mesylate - therapeutic use | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Imatinib Mesylate - adverse effects | Adolescent | Intention to Treat Analysis | Survival Analysis | Adult | Female | Aged | Cytogenetic Analysis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Care and treatment | Chronic myeloid leukemia | Patients | Health aspects | Prescription drugs | α-Interferon | Imatinib | Cytarabine | Myeloid leukemia | Medical prognosis | Interferon | Kinases | Survival | Index Medicus | Abridged Index Medicus | Inhibidors enzimàtics | Hematologia | Enzyme inhibitors | Hematology | Leucèmia mieloide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
by Hughes, Timothy P and Mauro, Michael J and Cortes, Jorge E and Minami, Yosuke and Minami, Hironobu and Rea, Delphine and DeAngelo, Daniel J and Breccia, Massimo and Goh, Yeow-Tee and Talpaz, Moshe and Hochhaus, Andreas and le Coutre, Philipp and Ottmann, Oliver and Heinrich, Michael C and Steegmann, Juan L and Deininger, Michael W.N and Janssen, Jeroen J.W.M and Mahon, Francois-Xavier and Yeung, David and Ross, David M and Tallman, Martin S and Park, Jae H and Druker, Brian J and Hynds, David and Duan, Yuyan and Meille, Christophe and Hourcade-Potelleret, Florence and Vanasse, K. Gary and Lang, Fabian and Kim, Dong-Wook
The New England journal of medicine, ISSN 0028-4793, 12/2019, Volume 381, Issue 24, pp. 2315 - 2326
d_article_not_yet_freely_accessible | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Niacinamide - analogs & derivatives | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Niacinamide - pharmacokinetics | Adult | Female | Antineoplastic Agents - pharmacokinetics | Pyrazoles - pharmacokinetics | Pyrazoles - adverse effects | Niacinamide - adverse effects | Logistic Models | Niacinamide - administration & dosage | Fusion Proteins, bcr-abl - genetics | Pyrazoles - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Aged | Mutation | Tyrosine | Thrombocytopenia | Headache | Myeloid leukemia | Leukemia | Arthralgia | Pancreatitis | Chronic myeloid leukemia | Lipase | Kinases | Patients | Philadelphia chromosome | Side effects | Allosteric properties | Cytogenetics | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
by O'Brien, Stephen G and Guilhot, François and Larson, Richard A and Gathmann, Insa and Baccarani, Michele and Cervantes, Francisco and Cornelissen, Jan J and Fischer, Thomas and Hochhaus, Andreas and Hughes, Timothy and Lechner, Klaus and Nielsen, Johan L and Rousselot, Philippe and Reiffers, Josy and Saglio, Giuseppe and Shepherd, John and Simonsson, Bengt and Gratwohl, Alois and Goldman, John M and Kantarjian, Hagop and Taylor, Kerry and Verhoef, Gregor and Bolton, Ann E and Capdeville, Renaud and Druker, Brian J and IRIS Investigators
The New England journal of medicine, ISSN 0028-4793, 03/2003, Volume 348, Issue 11, pp. 994 - 1004
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | Medical sciences | Blood. Blood coagulation. Reticuloendothelial system | Pharmacology. Drug treatments | Prospective Studies | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Middle Aged | Male | Survival Rate | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Antineoplastic Agents - administration & dosage | Imatinib Mesylate | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Adult | Female | Aged | Benzamides | Chronic myeloid leukemia | Pharmaceutical industry | Drug therapy | Product information | Clinical trials | Leukemia | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights